Status:
NOT_YET_RECRUITING
Upfront Premedication For Reduction of Microvascular Obstruction and No-reflow in Treating ST-segment Elevation Myocardial Infarction
Lead Sponsor:
Cairo University
Collaborating Sponsors:
Aswan Heart Centre
Conditions:
STEMI
Large Thrombus Burden
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Angiographic no-reflow during primary PCI procedures occurs at relatively high rate (25%) and is associated with worsening of long term morbidity and mortality. The exact mechanism of no-reflow is not...
Detailed Description
A. Study Design This study will be a randomized single blinded prospective study including acute STEMI patients presenting to Aswan heart centre catheterization-lab for pPCI. All patients will undergo...
Eligibility Criteria
Inclusion
- STEMI patients with time from symptom onset of \< 24 hours duration.
- Large thrombus burden confirmed after initial wiring.
- Radial vascular access.
Exclusion
- STEMI patients receiving successful fibrinolytic therapy.
- TIMI flow ≥ 1 or TIMI thrombus grade ≤ 3 at initial wiring.
- Refusal to participate int the study, or unable to be consented (unconscious or comatose patients).
- Femoral access.
- Previous infarction in the same territory.
- Patients receiving PTCA only for acute reperfusion and planned for CABG.
- Patients with known intolerance or contraindications for CMR, such as claustrophobic or those with mechanical heart valve prothesis, or implantable non-conditional heart rhythm devices.
Key Trial Info
Start Date :
January 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 30 2026
Estimated Enrollment :
626 Patients enrolled
Trial Details
Trial ID
NCT05393557
Start Date
January 1 2024
End Date
November 30 2026
Last Update
August 31 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.